Allergic reaction to high-dose methotrexate.
Postovsky
S
S
Department of Pediatric Hemato-Oncology, Rambam Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Elhasid
R
R
Ben-Barak
A
A
Levin
K
K
Ben Arush
M W
MW
D000293:Adolescent; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000982:Antipruritics / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy; D004155:Diphenhydramine / Q000627:therapeutic use; D003875:Drug Eruptions / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005493:Folic Acid Antagonists / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use; D012516:Osteosarcoma / Q000188:drug therapy; D011292:Premedication; D013977:Tibia; D014581:Urticaria / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*
D014151:Anti-Anxiety Agents; D000964:Antimetabolites, Antineoplastic; D000982:Antipruritics; D005493:Folic Acid Antagonists; D007166:Immunosuppressive Agents; D017294:Ondansetron; D004155:Diphenhydramine; D008727:Methotrexate